FY2027 EPS Estimates for Novartis Decreased by Analyst

Novartis AG (NYSE:NVS) – Analysts at Erste Group Bank dropped their FY2027 EPS estimates for Novartis in a report released on Thursday, August 27th. Erste Group Bank analyst H. Engel now forecasts that the company will post earnings of $9.80 per share for the year, down from their previous estimate of $9.82. The consensus estimate for Novartis’ current full-year earnings is $8.84 per share.

Novartis (NYSE:NVS) last issued its quarterly earnings data on Tuesday, June 30th. The company reported $2.41 earnings per share (EPS) for the quarter. Novartis had a net margin of 23.29% and a return on equity of 38.56%. The business had revenue of $14.95 billion during the quarter.

Other analysts also recently issued reports about the company. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Novartis in a research report on Friday, July 24th. Citigroup reissued a “buy” rating on shares of Novartis in a research report on Wednesday, July 22nd. Seven research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $141.20.

Novartis Price Performance

Shares of NYSE NVS opened at $152.22 on Tuesday. Novartis has a twelve month low of $121.57 and a twelve month high of $170.46. The stock’s 50 day moving average price is $155.14 and its 200-day moving average price is $153.72. The company has a market capitalization of $290.46 billion, a PE ratio of 22.96, a PEG ratio of 2.64 and a beta of 0.45. The company has a quick ratio of 0.67, a current ratio of 0.86 and a debt-to-equity ratio of 0.89.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of NVS. J.W. Cole Advisors Inc. increased its stake in shares of Novartis by 0.6% during the 4th quarter. J.W. Cole Advisors Inc. now owns 10,577 shares of the company’s stock worth $1,348,000 after purchasing an additional 64 shares during the last quarter. Roundview Capital LLC lifted its stake in Novartis by 2.5% in the fourth quarter. Roundview Capital LLC now owns 2,711 shares of the company’s stock valued at $374,000 after purchasing an additional 66 shares during the last quarter. CPC Advisors LLC grew its holdings in Novartis by 4.6% during the second quarter. CPC Advisors LLC now owns 1,516 shares of the company’s stock valued at $238,000 after purchasing an additional 66 shares during the period. IMA Advisory Services Inc. grew its holdings in Novartis by 10.9% during the fourth quarter. IMA Advisory Services Inc. now owns 710 shares of the company’s stock valued at $98,000 after purchasing an additional 70 shares during the period. Finally, Moody National Bank Trust Division increased its position in Novartis by 4.2% in the second quarter. Moody National Bank Trust Division now owns 1,802 shares of the company’s stock worth $282,000 after buying an additional 72 shares during the last quarter. 13.12% of the stock is owned by institutional investors.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.